Summary
The AI response asserts a roflumilast tablet dose (500 mcg daily) not supported by the provided label, which only describes topical ZORYVE dosing. It acknowledges topical dosing but introduces external (oral) dosing references not present in the supplied label.
Category Scores
Accurate Statements
The label indicates ZORYVE (roflumilast) is for topical use only and not for ophthalmic, oral, or intravaginal use.
2 Dosage and Administration
Dosage forms listed are topical creams (0.3%, 0.15%, 0.05%) per gram, not an oral tablet.
3 Dosage Forms and Strengths
Unsupported Statements
Dosing for roflumilast: one 500 mcg tablet daily.
Not supported by the provided label data; the label only describes topical roflumilast (ZORYVE) dosing and does not mention an oral tablet formulation or dosing.
Contradictions
Low
AI Statement
The claim 'Dosing for roflumilast: one 500 mcg tablet daily' is contradicted by the label (topical roflumilast; no oral tablet dosing).
Label Reference
2, 3
Important Omissions
Indications for ZORYVE (plaque psoriasis in adults and pediatric patients 2 years and older; atopic dermatitis in adults and pediatric patients 6 years and older) are not discussed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Misstating an oral roflumilast dose could lead to inappropriate use if generalized beyond the topical product; however, the label content evaluated concerns topical dosing and does not present new safety risks beyond those stated in the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Claim about oral roflumilast dosing is not supported by the provided label.
Suggested Improvement
Limit dosing statements to the product form described in the label (topical ZORYVE) and avoid extrapolating to oral roflumilast dosing; if discussing oral roflumilast, reference the appropriate oral product label separately.